A Phase II Trial Of Ipilimumab In Combination With Nivolumab In Patients With Advanced Nasopharyngeal Carcinoma
Latest Information Update: 13 Oct 2023
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
- 09 Oct 2023 Planned End Date changed from 1 Mar 2023 to 31 Dec 2024.
- 09 Oct 2023 Planned primary completion date changed from 1 Mar 2023 to 31 Dec 2024.
- 20 Jul 2022 Planned number of patients changed from 40 to 113.